CIK 0002096997 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Kailera Therapeutics, Inc.
Sign in to watch- Ticker
- KLRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 508-440-9475
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC 10% owner | Conversion | +16,875,000 | 16,875,000 | ||
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC 10% owner | Conversion | +4,145,768 | 21,020,768 | ||
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC 10% owner | Purchase | +1,562,500 | $16.00 | $25.0M | 22,583,268 |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC 10% owner | Conversion · Series A-1 Preferred Stock | −16,875,000 | 0 | ||
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC 10% owner | Conversion · Series B Preferred Stock | −4,145,768 | 0 | ||
| 2026-04-20 | Kaplan Andrew T. Director | Conversion | +17,857,143 | 17,857,143 | ||
| 2026-04-20 | Kaplan Andrew T. Director | Purchase | +8,398,438 | $16.00 | $134.4M | 26,255,581 |
| 2026-04-20 | Kaplan Andrew T. Director | Conversion · Series B Preferred Stock | −17,857,143 | 0 | ||
| 2026-04-16 | Koppel Adam Director | Grant or award · Stock Option (right to buy) | +38,300 | 38,300 | ||
| 2026-04-16 | Kaplan Andrew T. Director | Grant or award · Stock Option (right to buy) | +38,300 | 38,300 | ||
| 2026-04-16 | Cloghessy Paula Chief People Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2026-04-16 | Cloghessy Paula Chief People Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2026-04-16 | Akamine Scott Chief Legal Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2026-04-16 | Akamine Scott Chief Legal Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2026-04-16 | Renaud Ronald C JR CEO & President | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2026-04-16 | Renaud Ronald C JR CEO & President | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2026-04-16 | Burgess Paul D. See Remarks | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2026-04-16 | Burgess Paul D. See Remarks | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2026-04-16 | MILLIGAN JOHN F Director | Grant or award · Stock Option (right to buy) | +38,300 | 38,300 | ||
| 2026-04-16 | Coleman Jamie Beth Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +75,000 | 75,000 |
Page 2 of 3 · 48 trades